Does the media prefer VAL or SUN?

In the previous week, ValiRx had 4 more articles in the media than Surgical Innovations Group. MarketBeat recorded 5 mentions for ValiRx and 1 mentions for Surgical Innovations Group. Surgical Innovations Group's average media sentiment score of 0.00 beat ValiRx's score of -0.45 indicating that Surgical Innovations Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ValiRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Surgical Innovations Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is VAL or WRES more profitable?

W Resources has a net margin of -174.96% compared to ValiRx's net margin of -3,582.56%. W Resources' return on equity of -33.02% beat ValiRx's return on equity. Company Net Margins Return on Equity Return on Assets ValiRx -3,582.56% -45.91% -35.98% W Resources -174.96% -33.02% -2.04%

Which has higher earnings and valuation, VAL or EQT?

ValiRx has higher earnings, but lower revenue than EQTEC. ValiRx is trading at a lower price-to-earnings ratio than EQTEC, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ValiRx £49.78K 25.67 -£5.71M -£0.93 N/A EQTEC £1.39M 0.12 -£24.55M -£5.57 N/A

Is VAL or EQT more profitable?

EQTEC has a net margin of 0.00% compared to ValiRx's net margin of -3,582.56%. ValiRx's return on equity of -45.91% beat EQTEC's return on equity. Company Net Margins Return on Equity Return on Assets ValiRx -3,582.56% -45.91% -35.98% EQTEC N/A -83.34% -14.55%

Does the media refer more to VAL or EQT?

In the previous week, ValiRx had 4 more articles in the media than EQTEC. MarketBeat recorded 5 mentions for ValiRx and 1 mentions for EQTEC. EQTEC's average media sentiment score of 0.46 beat ValiRx's score of -0.45 indicating that EQTEC is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ValiRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral EQTEC 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, WEB or VAL?

Webis has higher revenue and earnings than ValiRx. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Webis £49.70M 0.00 N/A N/A N/A ValiRx £49.78K 25.67 -£5.71M -£0.93 N/A

Is WEB or VAL more profitable?

Webis has a net margin of -1.93% compared to ValiRx's net margin of -3,582.56%. ValiRx's return on equity of -45.91% beat Webis' return on equity. Company Net Margins Return on Equity Return on Assets Webis -1.93% -187.51% -8.29% ValiRx -3,582.56% -45.91% -35.98%

Does the media prefer WEB or VAL?

In the previous week, ValiRx had 3 more articles in the media than Webis. MarketBeat recorded 5 mentions for ValiRx and 2 mentions for Webis. Webis' average media sentiment score of 0.00 beat ValiRx's score of -0.45 indicating that Webis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Webis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ValiRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

ValiRx (VAL) Competitors

GBX 0.17 0.00 (-1.71%)

As of 11:57 AM Eastern

Compare

VAL vs. SUN, WRES, CRC, EQT, and WEB

Should you buy ValiRx stock or one of its competitors? MarketBeat compares ValiRx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ValiRx include Surgical Innovations Group (SUN), W Resources (WRES), Circle Property (CRC), EQTEC (EQT), and Webis (WEB). These companies are all part of the "petroleum and natural gas" industry.

How does ValiRx compare to Surgical Innovations Group?

ValiRx (LON:VAL) and Surgical Innovations Group (LON:SUN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

35.4% of ValiRx shares are held by institutional investors. Comparatively, 2.8% of Surgical Innovations Group shares are held by institutional investors. 12.9% of ValiRx shares are held by company insiders. Comparatively, 21.5% of Surgical Innovations Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, ValiRx had 4 more articles in the media than Surgical Innovations Group. MarketBeat recorded 5 mentions for ValiRx and 1 mentions for Surgical Innovations Group. Surgical Innovations Group's average media sentiment score of 0.00 beat ValiRx's score of -0.45 indicating that Surgical Innovations Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ValiRx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Surgical Innovations Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Surgical Innovations Group has a net margin of -4.96% compared to ValiRx's net margin of -3,582.56%. Surgical Innovations Group's return on equity of -6.04% beat ValiRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ValiRx	-3,582.56%	-45.91%	-35.98%
Surgical Innovations Group	-4.96%	-6.04%	-3.03%

ValiRx has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, Surgical Innovations Group has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

Surgical Innovations Group has higher revenue and earnings than ValiRx. Surgical Innovations Group is trading at a lower price-to-earnings ratio than ValiRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ValiRx	£49.78K	25.67	-£5.71M	-£0.93	N/A
Surgical Innovations Group	£11.60M	0.36	N/A	-£0.10	N/A

Summary

Surgical Innovations Group beats ValiRx on 8 of the 12 factors compared between the two stocks.

How does ValiRx compare to W Resources?

ValiRx (LON:VAL) and W Resources (LON:WRES) are both small-cap petroleum and natural gas companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

In the previous week, ValiRx had 5 more articles in the media than W Resources. MarketBeat recorded 5 mentions for ValiRx and 0 mentions for W Resources. W Resources' average media sentiment score of 0.00 beat ValiRx's score of -0.45 indicating that W Resources is being referred to more favorably in the news media.

Company	Overall Sentiment
ValiRx	Neutral
W Resources	Neutral

ValiRx has higher earnings, but lower revenue than W Resources. ValiRx is trading at a lower price-to-earnings ratio than W Resources, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ValiRx	£49.78K	25.67	-£5.71M	-£0.93	N/A
W Resources	£3.47M	0.00	-£6.06M	-£6.10	N/A

W Resources has a net margin of -174.96% compared to ValiRx's net margin of -3,582.56%. W Resources' return on equity of -33.02% beat ValiRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ValiRx	-3,582.56%	-45.91%	-35.98%
W Resources	-174.96%	-33.02%	-2.04%

ValiRx has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, W Resources has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

35.4% of ValiRx shares are held by institutional investors. Comparatively, 4.6% of W Resources shares are held by institutional investors. 12.9% of ValiRx shares are held by company insiders. Comparatively, 28.0% of W Resources shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

W Resources beats ValiRx on 7 of the 12 factors compared between the two stocks.

How does ValiRx compare to Circle Property?

Circle Property (LON:CRC) and ValiRx (LON:VAL) are both small-cap petroleum and natural gas companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

11.4% of Circle Property shares are held by institutional investors. Comparatively, 35.4% of ValiRx shares are held by institutional investors. 63.7% of Circle Property shares are held by company insiders. Comparatively, 12.9% of ValiRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Circle Property has higher revenue and earnings than ValiRx. ValiRx is trading at a lower price-to-earnings ratio than Circle Property, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Circle Property	£7.57M	0.00	£2.43M	£0.07	N/A
ValiRx	£49.78K	25.67	-£5.71M	-£0.93	N/A

In the previous week, ValiRx had 5 more articles in the media than Circle Property. MarketBeat recorded 5 mentions for ValiRx and 0 mentions for Circle Property. Circle Property's average media sentiment score of 0.00 beat ValiRx's score of -0.45 indicating that Circle Property is being referred to more favorably in the media.

Company	Overall Sentiment
Circle Property	Neutral
ValiRx	Neutral

Circle Property has a net margin of 32.17% compared to ValiRx's net margin of -3,582.56%. Circle Property's return on equity of 3.15% beat ValiRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Circle Property	32.17%	3.15%	1.48%
ValiRx	-3,582.56%	-45.91%	-35.98%

Circle Property has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, ValiRx has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market.

Summary

Circle Property beats ValiRx on 9 of the 12 factors compared between the two stocks.

How does ValiRx compare to EQTEC?

ValiRx (LON:VAL) and EQTEC (LON:EQT) are both small-cap petroleum and natural gas companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, ValiRx had 4 more articles in the media than EQTEC. MarketBeat recorded 5 mentions for ValiRx and 1 mentions for EQTEC. EQTEC's average media sentiment score of 0.46 beat ValiRx's score of -0.45 indicating that EQTEC is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ValiRx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
EQTEC	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

EQTEC has a net margin of 0.00% compared to ValiRx's net margin of -3,582.56%. ValiRx's return on equity of -45.91% beat EQTEC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ValiRx	-3,582.56%	-45.91%	-35.98%
EQTEC	N/A	-83.34%	-14.55%

35.4% of ValiRx shares are held by institutional investors. Comparatively, 11.8% of EQTEC shares are held by institutional investors. 12.9% of ValiRx shares are held by insiders. Comparatively, 6.3% of EQTEC shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ValiRx has higher earnings, but lower revenue than EQTEC. ValiRx is trading at a lower price-to-earnings ratio than EQTEC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ValiRx	£49.78K	25.67	-£5.71M	-£0.93	N/A
EQTEC	£1.39M	0.12	-£24.55M	-£5.57	N/A

ValiRx has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, EQTEC has a beta of 2.07, indicating that its stock price is 107% more volatile than the broader market.

Summary

ValiRx beats EQTEC on 7 of the 13 factors compared between the two stocks.

How does ValiRx compare to Webis?

Webis (LON:WEB) and ValiRx (LON:VAL) are both small-cap petroleum and natural gas companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Webis has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, ValiRx has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

In the previous week, ValiRx had 3 more articles in the media than Webis. MarketBeat recorded 5 mentions for ValiRx and 2 mentions for Webis. Webis' average media sentiment score of 0.00 beat ValiRx's score of -0.45 indicating that Webis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Webis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ValiRx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Webis has a net margin of -1.93% compared to ValiRx's net margin of -3,582.56%. ValiRx's return on equity of -45.91% beat Webis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Webis	-1.93%	-187.51%	-8.29%
ValiRx	-3,582.56%	-45.91%	-35.98%

Webis has higher revenue and earnings than ValiRx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Webis	£49.70M	0.00	N/A	N/A	N/A
ValiRx	£49.78K	25.67	-£5.71M	-£0.93	N/A

35.4% of ValiRx shares are owned by institutional investors. 63.1% of Webis shares are owned by insiders. Comparatively, 12.9% of ValiRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Webis beats ValiRx on 7 of the 10 factors compared between the two stocks.

Get ValiRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VAL vs. The Competition

Export

Metric	ValiRx	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£1.28M	£476.97M	£6.56B	£2.77B
Dividend Yield	0.63%	3.86%	2.69%	6.16%
P/E Ratio	-0.18	3.18	25.23	366.61
Price / Sales	25.67	6,523.20	555.61	86,103.13
Price / Cash	62.50	13.13	44.82	27.87
Price / Book	0.06	90.34	10.83	7.85
Net Income	-£5.71M	-£96.07M	£3.56B	£5.89B
7 Day Performance	-8.51%	1.06%	1.97%	-0.97%
1 Month Performance	-9.47%	0.49%	1.40%	-0.79%
1 Year Performance	-72.83%	65.99%	31.18%	68.89%

ValiRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VAL ValiRx	N/A	GBX 0.17 -1.7%	N/A	-70.1%	£1.28M	£49.78K	N/A	5,450	News Coverage Earnings Report
SUN Surgical Innovations Group	N/A	GBX 0.45 -2.4%	N/A	-32.7%	£4.20M	£11.60M	N/A	80	News Coverage Positive News Gap Down
WRES W Resources	N/A	N/A	N/A	N/A	£3.89M	£3.47M	N/A	66	Gap Down
CRC Circle Property	N/A	N/A	N/A	N/A	£1.02M	£7.57M	50.00	1,060	Gap Down High Trading Volume
EQT EQTEC	N/A	GBX 0.02 flat	N/A	-97.4%	£179K	£1.39M	N/A	740	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:VAL) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ValiRx (VAL) Competitors

VAL vs. SUN, WRES, CRC, EQT, and WEB

How does ValiRx compare to Surgical Innovations Group?

Summary

How does ValiRx compare to W Resources?

Summary

How does ValiRx compare to Circle Property?

Summary

How does ValiRx compare to EQTEC?

Summary

How does ValiRx compare to Webis?

Summary

Media Sentiment Over Time

VAL vs. The Competition

ValiRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ValiRx (VAL) Competitors

VAL vs. SUN, WRES, CRC, EQT, and WEB

How does ValiRx compare to Surgical Innovations Group?

Do institutionals and insiders hold more shares of VAL or SUN?

Does the media prefer VAL or SUN?

Is VAL or SUN more profitable?

Which has more risk & volatility, VAL or SUN?

Which has better valuation & earnings, VAL or SUN?

Summary

How does ValiRx compare to W Resources?

Does the media prefer VAL or WRES?

Which has stronger valuation and earnings, VAL or WRES?

Is VAL or WRES more profitable?

Which has more volatility and risk, VAL or WRES?

Do institutionals and insiders believe in VAL or WRES?

Summary

How does ValiRx compare to Circle Property?

Do institutionals & insiders hold more shares of CRC or VAL?

Which has better earnings and valuation, CRC or VAL?

Does the media prefer CRC or VAL?

Is CRC or VAL more profitable?

Which has more volatility & risk, CRC or VAL?

Summary

How does ValiRx compare to EQTEC?

Does the media refer more to VAL or EQT?

Is VAL or EQT more profitable?

Do institutionals and insiders have more ownership in VAL or EQT?

Which has higher earnings and valuation, VAL or EQT?

Which has more risk & volatility, VAL or EQT?

Summary

How does ValiRx compare to Webis?

Which has more volatility & risk, WEB or VAL?

Does the media prefer WEB or VAL?

Is WEB or VAL more profitable?

Which has higher earnings & valuation, WEB or VAL?

Do insiders and institutionals believe in WEB or VAL?

Summary

Media Sentiment Over Time

VAL vs. The Competition

ValiRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools